Mitochondrial transplantation is an emerging therapeutic approach for ischemia-reperfusion injury, offering the potential to restore cellular function through the engraftment of extracellular mitochondria. The successful clinical application of this strategy depends on the delivery of metabolically active mitochondria, yet the impact of circulating therapeutic agents on mitochondrial viability remains poorly understood. This study evaluates the effects of five clinically relevant agents commonly used during endovascular treatment of ischemic stroke—alteplase, cefazolin, lidocaine, phenylephrine, and heparinized saline—on extracellular mitochondria using an ex vivo model. Mitochondria were isolated from human skeletal muscle and mouse liver and exposed to these agents at clinically relevant and supra-physiological concentrations. Metabolic activity was assessed using a resazurin reduction assay as an indicator of mitochondrial viability. Even at concentrations up to 8-fold above clinical exposure, none of the agents significantly impaired mitochondrial function. These findings provide critical toxicological data demonstrating the compatibility of commonly used therapeutics with mitochondrial transplantation, supporting the development of safer and more optimized clinical protocols.
McCullyJDCowanDBEmaniSM, et al.
Mitochondrial transplantation: from animal models to clinical use in humans. Mitochondrion2017;
34: 127–134.
2.
GuarientoABlitzerDDoulamisI, et al.
Preischemic autologous mitochondrial transplantation by intracoronary injection for myocardial protection. J Thorac Cardiovasc Surg2020;
160: e15–e29.
3.
MoskowitzovaKOrfanyALiuK, et al.
Mitochondrial transplantation enhances murine lung viability and recovery after ischemia-reperfusion injury. Am J Physiol Lung Cell Mol Physiol2020;
318: L78–L88.
4.
GuarientoAPiekarskiBLDoulamisIP, et al.
Autologous mitochondrial transplantation for cardiogenic shock in pediatric patients following ischemia-reperfusion injury. J Thorac Cardiovasc Surg2021;
162: 992–1001.
5.
NoratPSokolowskiJDGorickCM, et al.
Intraarterial transplantation of mitochondria after ischemic stroke reduces cerebral infarction. Stroke Vasc Interv Neurol2023;
3.
6.
WalkerMLevittMRFedericoEM, et al.
Autologous mitochondrial transplant for acute cerebral ischemia: phase 1 trial results and review. J Cereb Blood Flow Metab2024; 271678X241305230.
7.
LinY-TLinK-HHuangC-J, et al.
MitoTox: a comprehensive mitochondrial toxicity database. BMC Bioinformatics2021;
22: 369.
8.
DykensJAWillY.The significance of mitochondrial toxicity testing in drug development. Drug Discov Today2007;
12: 777–785.
9.
RosenthalMFengZCRaffinCN, et al.
Mitochondrial hyperoxidation signals residual intracellular dysfunction after global ischemia in rat neocortex. J Cereb Blood Flow Metab1995;
15: 655–665.
AcheampongPFordGA.Pharmacokinetics of alteplase in the treatment of ischaemic stroke. Expert Opin Drug Metab Toxicol2012;
8: 271–281.
12.
RånbyM.Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta1982;
704: 461–469.
13.
LindgrenALindoffCNorrvingB, et al.
Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke1996;
27: 1066–1071.
14.
BerganT.Comparative pharmacokinetics of cefazolin, cephalothin, cephacetril, and cephapirine after intravenous administration. Chemotherapy1977;
23: 389–404.
15.
BrogardJMComteFPingetM.Pharmacokinetics of cephalosporin antibiotics. Antibiot Chemother (1971)1978;
25: 123–162.
16.
AndrioleVT.Pharmacokinetics of cephalosporins in patients with normal or reduced renal function. J Infect Dis1978;
137 Suppl: S88–S99.
17.
BeaussierMDelbosAMaurice-SzamburskiA, et al.
Perioperative use of intravenous lidocaine. Drugs2018;
78: 1229–1246.
18.
ButterworthJFStrichartzGR.Molecular mechanisms of local anesthesia: a review. Anesthesiology1990;
72: 711–734.
19.
TarbaCCrăciumC.A comparative study of the effects of procaine, lidocaine, tetracaine and dibucaine on the functions and ultrastructure of isolated rat liver mitochondria. Biochim Biophys Acta1990;
1019: 19–28.
GoradiaSSardanehAANarayanSW, et al.
Vasopressor dose equivalence: a scoping review and suggested formula. J Crit Care2021;
61: 233–240.
23.
Robertson-MaltSMaltGNFarquharV, et al.
Heparin versus normal saline for patency of arterial lines. Cochrane Database Syst Rev2014;
2014: CD007364.
24.
HogwoodJMulloyBLeverR, et al.
Pharmacology of heparin and related drugs: an update. Pharmacol Rev2023;
75: 328–379.
25.
CapilaILinhardtRJ.Heparin-protein interactions. Angew Chem Int Ed Engl2002;
41: 391–412.
26.
OlofssonAMVestbergMHerwaldH, et al.
Heparin-binding protein targeted to mitochondrial compartments protects endothelial cells from apoptosis. J Clin Invest1999;
104: 885–894.
27.
PrebleJMPacakCAKondoH, et al.
Rapid isolation and purification of mitochondria for transplantation by tissue dissociation and differential filtration. J Vis Exp2014; e51682.
28.
FrezzaCCipolatSScorranoL.Organelle isolation: functional mitochondria from mouse liver, muscle and cultured filroblasts. Nat Protoc2007;
2: 287–295.
GreyJFETownleyAREverittNM, et al.
A cost-effective, analytical method for measuring metabolic load of mitochondria. Metabol Open2019;
4: 100020.
31.
ZhangH-XDuG-HZhangJ-T.Assay of mitochondrial functions by resazurin in vitro. Acta Pharmacol Sin2004;
25: 385–389.
32.
O'BrienJWilsonIOrtonT, et al.
Investigation of the alamar blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem2000;
267: 5421–5426.
33.
TanswellPTebbeUNeuhausKL, et al.
Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol1992;
19: 1071–1075.
34.
WeinsteinAJ.The cephalosporins: activity and clinical use. Drugs1980;
20: 137–154.
35.
CooperBE.Review and update on inotropes and vasopressors. AACN Adv Crit Care2008;
19: 5–13. quiz 14: –5.
36.
OnishiASt AngeKDordickJS, et al.
Heparin and anticoagulation. Front Biosci (Landmark Ed)2016;
21: 1372–1392.
37.
KarninaRArifSKHattaM, et al.
Molecular mechanisms of lidocaine. Ann Med Surg (Lond)2021;
69: 102733.
38.
DominicAHamiltonDAbeJ-I.Mitochondria and chronic effects of cancer therapeutics: the clinical implications. J Thromb Thrombolysis2021;
51: 884–889.
39.
CohenPJ.Effect of anesthetics on mitochondrial function. Anesthesiology1973;
39: 153–164.
40.
NahrwoldMLCohenPJ.Anesthetics and mitochondrial respiration. Clin Anesth1975;
11: 25–44.
41.
PicardMMcEwenBSEpelES, et al.
An energetic view of stress: focus on mitochondria. Front Neuroendocrinol2018;
49: 72–85.
42.
HayakawaKEspositoEWangX, et al.
Transfer of mitochondria from astrocytes to neurons after stroke. Nature2016;
535: 551–555.
43.
RampersadSN.Multiple applications of alamar blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sensors (Basel)2012;
12: 12347–12360.
44.
OwenMRDoranEHalestrapAP.Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J2000;
348 Pt 3: 607–614.
45.
TimperKDel Río-MartínACremerAL, et al.
GLP-1 receptor signaling in astrocytes regulates fatty acid oxidation, mitochondrial integrity, and function. Cell Metab2020;
31: 1189–1205.e13.
46.
NylanderEZellerothSNybergF, et al.
The effects of morphine, methadone, and fentanyl on mitochondria: a live cell imaging study. Brain Res Bull2021;
171: 126–134.
47.
JayanthiSDaiwileAPCadetJL.Neurotoxicity of methamphetamine: main effects and mechanisms. Exp Neurol2021;
344: 113795.
